-
Open Access Emergency Medicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease
Review
(2434) Views (1114) Full article downloads
Authors: T S Mohamed Saleem, K Bharani, K Gauthaman
Published Date July 2010
Volume 2010:2 Pages 51 - 59
DOI: http://dx.doi.org/10.2147/OAEM.S10507
T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, Libya
Abstract: Morbidity and mortality from cardiovascular diseases are still high, even with the use of the best available therapies. There is mounting evidence that excessive renin-angiotensin system activation triggers much of the damaging and progressive nature of cardiovascular and kidney diseases through expression of angiotensin II. Moreover, angiotensin II play a major role in the development of end organ damage through a variety of inflammatory mechanisms. Today, angiotensins-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists have clearly demonstrated their efficacy in preventing target organ damage and in reducing cardiovascular morbidity and mortality in ischemic heart disease (IHD). Moreover, the development of angiotensin II receptor antagonists has enabled a large gain in tolerability and safety. Several clinical trials have firmly established that these drugs act on the renin–angiotensin system, reducing the incidence of coronary events with monotherapy and combination therapy. In this review we summarize the role mono- and combined therapy of ACE inhibitors and angiotensin II receptor antagonists play in ischemic heart disease. In this respect the review will improve ideas for developing new formulations with combinations of these drugs in the future.
Keywords: angiotensin receptor blockers, renin angiotensin system, angiotensin II
Other articles by Mr TSM Saleem
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus
Readers of this article also read:
Dronedarone in the management of atrial fibrillation
Focused versus screening CT scans for evaluation of nontraumatic abdominal pain in the emergency department
Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole
Patient outcome in migraine prophylaxis: the role of psychopharmacological agents
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
Antimicrobial prophylaxis in open lower extremity fractures
The western diet and lifestyle and diseases of civilization
Clinical update on the use of biomarkers of airway inflammation in the management of asthma
Renal dysfunction prevalence and clinical impact in heart failure
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- An eight-week yoga intervention is associated with improvements in pain, psychological functioning and mindfulness, and changes in cortisol levels in women with fibromyalgia
- Problems and barriers of pain management in the emergency department: Are we ever going to get better?
- A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
- Anesthesiologists’ perception of patients’ anxiety under regional anesthesia




